Kenneth A. Freedberg, MD, is Professor of Medicine at Harvard Medical School and Massachusetts General Hospital and Director of the Program in Epidemiology and Outcomes Research at the Harvard University Center for AIDS Research (CFAR). He also directs the Medical Practice Evaluation Center within the Department of Medicine at Massachusetts General Hospital.
Dr. Freedberg's research interests focus on HIV, TB, as well as other chronic disease clinical outcomes and health policy, utilizing the methods of comparative effectiveness, cost-effectiveness analysis, clinical epidemiology, and implementation science. He is most interested in the intersection of clinical medicine and economics - to understand the "value" of health care.
His current research efforts are focused in the United States, France, Portugal, Brazil, South Africa, Cote d'Ivoire, Zimbabwe, Botswana, Mozambique and India. This NIH and foundation-funded work examines clinical policies for antiretroviral use, HIV testing, laboratory management, and HIV/TB co-infection.
The Medical Practice Evaluation Center team has a particular interest in informing guidelines in individual countries and across regions in both well-resourced and resource-limited settings. Collaborators include investigators in each of the countries above, as well as in HIV trials groups in the United States including the ACTG, IMPAACT, and the HPTN.
MGH Hotline 010909 Andrea Ciaranello, MD, MPH, of the MGH Infectious Disease Unit; and Kenneth A. Freedberg, MD, MSc, director of the MGH HIV Research Program in the Division of General Medicine, have received a grant from the Elizabeth Glaser Pediatric AIDS Foundation to study best practices in the fight against pediatric AIDS.
Eliminating new infant HIV infections in Zimbabwe will require not only improved access to antiretroviral medications but also support to help HIV-infected mothers continue taking their medication and safely reduce or eliminate breastfeeding, according to study led by MGH investigators.
"Treatment as prevention" – early initiation of antiretroviral therapy (ART) for HIV-infected individuals with uninfected sexual partners to prevent viral transmission – appears to make economic sense, along with meeting its clinical goals of helping infected patients stay healthy and reducing transmission.